The public offering will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-199849) previously filed with and declared effective by the
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Sorrento is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for immuno-oncology, inflammation and autoimmune diseases. Sorrento’s lead product candidates include immunotherapies focused on the treatment of both solid tumors and hematological malignancies, as well as late stage pain products.
This press release contains forward-looking statements related to
Sorrento® and the Sorrento logo are registered trademarks of
All other trademarks and trade names are the property of their respective owners.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sorrento-announces-proposed-public-offering-of-common-stock-300438904.html